[May 21, 2015]

Research and Markets: Heart Attack Pipeline Report 2015 - 3 Companies & 10 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/2fz463/heart_attack) has announced the addition of the "Heart Attack - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Heart Attack, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for eart Attack and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• APT (News - Alert) Therapeutics, Inc.
• Lacer, S.A.
• Lanthio Pharma B.V.

Drug Profiles

• AB-002
• APT-102
• Drugs to Inhibit Alpha Myosin for Cardiovascular Disorders
• LA-8045
• LWnt-3a
• Lysimab
• NVX-308
• Peptide to Agonize Apelin Receptor for Diabetes and Heart Failure
• Small Molecule for Reperfusion Injury and Heart Attack
• Small Molecules to Inhibit PDE5 for Cardiovascular Disease

For more information visit http://www.researchandmarkets.com/research/2fz463/heart_attack

View source version on businesswire.com: http://www.businesswire.com/news/home/20150521005601/en/

[ Back To TMCnet.com's Homepage ]